REG - Trellus Health PLC - AGM Statement

Trellus HealthAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd8593Oa&default-theme=true

RNS Number : 8593O  Trellus Health PLC  30 June 2025

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

AGM Statement

 

LONDON, U.K. AND NEW YORK, U.S. (30 June 2025). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announces it will hold its Annual General Meeting at 1.00pm (BST)
today at the Company's registered office, 201 Temple Chambers, 3-7 Temple
Avenue, London, United Kingdom, EC4Y 0DT.

 

Kevin L. Murphy Jr., Chairman will address the meeting with the following
update:

 

"We continue to focus on Trellus Health's key commercial verticals:
pharmaceutical patient support programs, clinical trial patient recruitment
and retention services, and the U.S. health plan sector. Notably, Trellus
Health has recently been granted preferred vendor status by a leading global
contract research organisation (CRO), and whilst not revenue generating in
itself, this reinforces the value of our proprietary resilience methodology.

 

"Our collaborative relationship with Johnson & Johnson remains strong and
we are already delivering on key early metrics of patient satisfaction ratings
and engagement.

 

"We have continued to maintain strong discipline in our cash management and
have further reduced our cost base from the average monthly burn of $500k,
year to date, as announced at our annual results. With effect from August 1
2025, our average monthly cash burn will be reduced to $440k per month. This
has been a focus of the Group, even as we expand our go-to-market strategy
within the pharmaceutical sector. These additional reductions have extended
the cash runway into mid-November 2025. The Company continues to evaluate all
commercial options, including ongoing discussions with a number of potential
commercial partners and discussions with professional advisers in relation to
fund raising options."

 

Enquiries:

 

 Trellus Health plc                                                     https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder            Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets
 Jen Boorer / James Todd / Jalini Kalaravy                             Tel: +44 (0)20 7496 3000

 Walbrook PR           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                       (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
 Alice Woodings                                                        +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer
hospitalisations and a reduction of over 70% in emergency room visits. Given
the common emotional and mental health struggles associated with a variety of
chronic conditions, Trellus Health considers its approach to have potential
utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners
from clinical trials to commercialisation, harnessing resilience-based methods
to drive both trial and patient support success by empowering patients to stay
engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMUKUSRVSUNUAR